药品
抗体
临床试验
免疫疗法
癌症
化疗
抗体-药物偶联物
肺癌
医学
肿瘤科
癌症研究
免疫学
药理学
单克隆抗体
内科学
作者
Chenyu Zhao,Ruihan Zhang,Huazhe Yang,Yiwei Gao,Ying Zou,Xudong Zhang
标识
DOI:10.1016/j.bcp.2024.116378
摘要
Lung cancer is the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all lung cancers and having a poor treatment and prognosis. Conventional clinical chemotherapy and immunotherapy are challenged by systemic toxicity and drug resistance, so researchers are increasingly focusing on antibody-drug conjugate (ADC), an innovative concept combining chemotherapy and targeted therapy, in which a drug selectively binds to antigens on the surface of a tumor cell via antibodies, which internalize the ADC, and then transfers the ADC to the lysosome via the endosomes to degrade the drug and kill the tumor cell. Despite the promising nature of ADCs, no ADC product for any indication including NSCLC has been approved for marketing by the FDA to date. In this review, we summarize the main advantages of ADCs and discuss in depth the design of the most desirable ADCs for NSCLC therapy. In addition to preclinical studies, we focus on the current state of clinical research on ADCs as interventions for the treatment of NSCLC by summarizing real-time clinical trial data from ClinicalTrials.gov, and reasonably speculate on the direction of the design of future generations of ADCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI